Zelalem Temesgen

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint The latest in antiretroviral therapy
    Zelalem Temesgen
    Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA
    Drug News Perspect 19:491-8. 2006
  2. doi request reprint Telaprevir: looking for a sustained virologic response in hepatitis C virus infection
    V Nehra
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Drugs Today (Barc) 47:829-37. 2011
  3. doi request reprint Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection
    Z Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Drugs Today (Barc) 50:7-14. 2014
  4. doi request reprint Cobicistat, a pharmacoenhancer for HIV treatments
    Z Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
    Drugs Today (Barc) 49:233-7. 2013
  5. doi request reprint Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection
    Z Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
    Drugs Today (Barc) 48:765-71. 2012
  6. doi request reprint Current status of treatment for chronic hepatitis C virus infection
    R Talwani
    Institute of Human Virology and Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Drugs Today (Barc) 48:219-31. 2012
  7. ncbi request reprint Interleukin-2 for the treatment of human immunodeficiency virus infection
    Zelalem Temesgen
    Division of Infectious Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 42:791-801. 2006
  8. ncbi request reprint Advances in antiretroviral therapy
    Zelalem Temesgen
    Mayo Clinic, Division of Infectious Diseases, Rochester, Minnesota 55905, USA
    Drug News Perspect 21:125-31. 2008
  9. ncbi request reprint Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico
    Zelalem Temesgen
    Mayo Clinic, Division of Infectious Diseases, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 18:549-53. 2009
  10. ncbi request reprint Micafungin - the newest echinocandin
    Zelalem Temesgen
    Mayo Clinic and Foundation, Division of Infectious Diseases, Rochester, MN 55905, USA
    Drugs Today (Barc) 45:469-78. 2009

Detail Information

Publications39

  1. ncbi request reprint The latest in antiretroviral therapy
    Zelalem Temesgen
    Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA
    Drug News Perspect 19:491-8. 2006
    ..It is not a lack of recognition of the other equally important topics and discussions that took place at AIDS 2006. The author is solely responsible for the selection of topics and presentations to be included in this report...
  2. doi request reprint Telaprevir: looking for a sustained virologic response in hepatitis C virus infection
    V Nehra
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Drugs Today (Barc) 47:829-37. 2011
    ..While the role of telaprevir in the management of chronic HCV infection remains to be fully defined, its development and licensure represents an important milestone in anti-HCV therapeutics...
  3. doi request reprint Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection
    Z Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Drugs Today (Barc) 50:7-14. 2014
    ..Furthermore, dolutegravir retains significant virologic activity against raltegravir- or elvitegravir-associated HIV-1 resistance mutations. ..
  4. doi request reprint Cobicistat, a pharmacoenhancer for HIV treatments
    Z Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
    Drugs Today (Barc) 49:233-7. 2013
    ..A fixed-dose combination product containing cobicistat in addition to elvitegravir, tenofovir and emtricitabine, and providing a one-pill, once-a-day, antiretroviral regimen was recently approved...
  5. doi request reprint Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection
    Z Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
    Drugs Today (Barc) 48:765-71. 2012
    ....
  6. doi request reprint Current status of treatment for chronic hepatitis C virus infection
    R Talwani
    Institute of Human Virology and Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Drugs Today (Barc) 48:219-31. 2012
    ..However, the drug development pipeline for chronic HCV infection is very robust and the emergence of new therapies and therapeutic strategies in the near future for managing chronic HCV infection is eagerly anticipated...
  7. ncbi request reprint Interleukin-2 for the treatment of human immunodeficiency virus infection
    Zelalem Temesgen
    Division of Infectious Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 42:791-801. 2006
    ..Large randomized clinical trials are underway to investigate whether these CD4 cell increments will result in tangible clinical benefits...
  8. ncbi request reprint Advances in antiretroviral therapy
    Zelalem Temesgen
    Mayo Clinic, Division of Infectious Diseases, Rochester, Minnesota 55905, USA
    Drug News Perspect 21:125-31. 2008
    ..This article focuses on presentations at the conference that directly dealt with antiretroviral therapy...
  9. ncbi request reprint Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico
    Zelalem Temesgen
    Mayo Clinic, Division of Infectious Diseases, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 18:549-53. 2009
    ..This report focuses on the main theme of the conference, the antiretroviral drug development pipeline. The author is solely responsible for the selection of topics and presentations to be included in this report...
  10. ncbi request reprint Micafungin - the newest echinocandin
    Zelalem Temesgen
    Mayo Clinic and Foundation, Division of Infectious Diseases, Rochester, MN 55905, USA
    Drugs Today (Barc) 45:469-78. 2009
    ..is generally well tolerated with few significant adverse effects...
  11. doi request reprint Boceprevir
    S A Rizza
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Drugs Today (Barc) 47:743-51. 2011
    ..Boceprevir is the first-in-class of an exciting new phase of HCV treatment...
  12. ncbi request reprint Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor
    Zelalem Temesgen
    Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Investig Drugs 7:759-65. 2006
    ..Phase II clinical trials are underway and phase III trials expected to commence in 2007...
  13. ncbi request reprint Current status of antiretroviral therapy
    Zelalem Temesgen
    Mayo Clinic and Foundation, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Pharmacother 7:1541-54. 2006
    ..A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided...
  14. ncbi request reprint HIV and drug allergy
    Zelalem Temesgen
    Division of Infectious Diseases, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Immunol Allergy Clin North Am 24:521-31, viii. 2004
    ..The authors provide an overview of these drug-related reactions and discuss their pathogenesis and management...
  15. ncbi request reprint Tipranavir
    Zelalem Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 41:711-20. 2005
    ..The most common adverse effects associated with tipranavir are diarrhea, nausea and vomiting. Common laboratory abnormalities include elevations of total cholesterol, triglycerides and liver enzymes...
  16. ncbi request reprint Comprehensive Health Enhancement Support System (CHESS) for people with HIV infection
    Zelalem Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA
    AIDS Behav 10:35-40. 2006
    ..Most participants agreed that CHESS was easy to use and helped them cope with and understand more about their disease. They also felt comfortable asking questions and felt more involved in their health care...
  17. ncbi request reprint Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults
    Zelalem Temesgen
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Lancet Infect Dis 6:496-507. 2006
    ..Additionally, increased mortality has been associated with multidrug-resistant HIV. We review data relevant to management of such patients and offer a systematic approach to constructing a salvage antiretroviral regimen...
  18. doi request reprint Etravirine
    Bettina M Knoll
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 44:23-33. 2008
    ..Because of its effect on the cytochrome P450 system, there are significant drug interaction issues that will need to be taken into consideration with its use...
  19. ncbi request reprint Maraviroc
    Hind Fadel
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Drugs Today (Barc) 43:749-58. 2007
    ..In these studies, maraviroc also demonstrated acceptable safety and tolerability profiles with adverse events and discontinuation rates in general comparable to those noted in the placebo arms...
  20. ncbi request reprint Antiretroviral therapy in HIV
    Aimee Yu
    Mayo Clinic College of Medicine, Rochester, MN, USA
    J Med Liban 54:74-9. 2006
    ..We also briefly discuss current guidelines regarding the use of antiretrovirals in general as well as in special populations such as in pregnant women, in occupational exposure and non occupational exposure...
  21. ncbi request reprint Tipranavir: a new option for the treatment of drug-resistant HIV infection
    Zelalem Temesgen
    Division of Infectious Diseases, Mayo Clinic and Foundation, Rochester, MN, USA
    Clin Infect Dis 45:761-9. 2007
    ....
  22. ncbi request reprint Initial antiretroviral therapy in chronically-infected HIV-positive adults
    Zelalem Temesgen
    Mayo Clinic and Foundation, Division of Infectious Diseases, Rochester, MN 55905, USA
    Expert Opin Pharmacother 5:595-612. 2004
    ....
  23. doi request reprint Current status of HIV infection: a review for non-HIV-treating physicians
    Bettina Knoll
    Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Int J Dermatol 46:1219-28. 2007
    ..Nevertheless, opportunistic infections and conditions continue to occur, and their recognition and management continue to be an important component of HIV care...
  24. ncbi request reprint Darunavir
    Wissam I El-Atrouni
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 43:671-9. 2007
    ..In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic responses superior to comparator-based regimens...
  25. ncbi request reprint Viral opportunistic infections in HIV-infected adults
    Constantine Tsigrelis
    Mayo Clinic College of Medicine, Rochester, MN, USA
    J Med Liban 54:91-6. 2006
    ....
  26. ncbi request reprint HIV-associated malignancies
    Francesca Cainelli
    Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
    J Med Liban 54:111-9. 2006
  27. ncbi request reprint Antiretroviral drugs
    David Warnke
    Mayo Clinic and Foundation, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Pharmacol 47:1570-9. 2007
    ..A synopsis of current antiretroviral treatment guidelines is also provided...
  28. ncbi request reprint SARS: epidemiology, clinical presentation, management, and infection control measures
    Priya Sampathkumar
    Division of Infectious Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:882-90. 2003
    ..This article summarizes currently available information regarding the epidemiology, clinical features, etiologic agent, and modes of transmission of the disease, as well as infection control measures appropriate to contain SARS...
  29. ncbi request reprint Osteoarticular infection complicating enterococcal endocarditis
    Nicholas E Vlahakis
    Division of Pulmonary and Critical Care Medicine and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:623-8. 2003
    ..This report highlights the rare occurrence of osteoarticular infection in the setting of enterococcal endocarditis and emphasizes early recognition and treatment...
  30. ncbi request reprint HIV-associated opportunistic infections. Bacterial infections
    Wissam El-Atrouni
    Mayo Clinic College of Medicine, Rochester, MN, USA
    J Med Liban 54:80-3. 2006
    ..Epidemiology, clinical presentation, diagnosis, treatment and prophylaxis are also reviewed...
  31. ncbi request reprint Opportunistic infections in patients with HIV and AIDS. Fungal and parasitic infections
    Jeffrey Martinez
    Mayo Clinic College of Medicine, Rochester, MN, USA
    J Med Liban 54:84-90. 2006
    ..In this manuscript, we review the epidemiology, clinical manifestations, diagnosis, and treatment of common fungal and parasitic opportunistic infections...
  32. pmc HIV screening in the health care setting: status, barriers, and potential solutions
    Stacey A Rizza
    Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
    Mayo Clin Proc 87:915-24. 2012
    ....
  33. pmc HIV lumbosacral radiculoplexus neuropathy mimicking lymphoma: diffuse infiltrative lymphocytosis syndrome (DILS) restricted to nerve?
    Nizar Chahin
    Peripheral Neuropathy Research Laboratory, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Muscle Nerve 41:276-82. 2010
    ..Symptoms, signs, and repeat biopsy improved with antiretroviral treatment. The presentation and treatment response suggest that this case is localized DILS...
  34. pmc Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans
    Kimberly P Liang
    Department of Medicine and Division of Infectious Diseases, Mayo Clinic College of Medicine, 200 First St SW, Rochester, Minnesota 55905, USA
    J Clin Microbiol 44:892-8. 2006
    ..Most such infections occurred in immunocompetent patients, often after facial trauma. Survival in ROCM caused by A. elegans is favorable in reported cases, with prompt surgical debridement and antifungal therapy...
  35. ncbi request reprint Interleukin-2 therapy and CD4+ T cells in HIV-1 infection
    Sandro Vento
    Section of Infectious Diseases, Department of Pathology, University of Verona, 37138 Verona, Italy
    Lancet 367:93-5. 2006
  36. ncbi request reprint Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 43:1031-9. 2006
  37. ncbi request reprint Intestinal spirochetosis and diarrhea, commensal or causal
    Matthew W Martinez
    AIDS 18:2441-2. 2004
  38. ncbi request reprint Human immunodeficiency virus-associated peripheral neuropathies
    Sergio Ferrari
    Department of Neurological and Visual Sciences, Section of Neurology, University of Verona, Verona, Italy
    Mayo Clin Proc 81:213-9. 2006
    ....
  39. doi request reprint Screening and assessment of coronary heart disease in HIV-infected patients
    Priscilla Y Hsue
    Circulation 118:e41-7. 2008